Tirzepatide vs Semaglutide: GLP-1 Comparison Guide
Tirzepatide vs semaglutide comparison: mechanism, weight loss (22.5% vs 14.9%), A1C reduction, cost, and which patients may benefit more from each.
Quick Answer: Tirzepatide produces greater average weight loss than semaglutide in clinical trials (~22.5% vs ~14.9%) due to its dual GIP+GLP-1 mechanism. Both are weekly injections, but tirzepatide costs slightly more without insurance.
Tirzepatide and semaglutide are both injectable medications used for weight loss and type 2 diabetes, and both work on the GLP-1 receptor. That's where much of the similarity ends. The mechanism difference between these two drugs has real clinical consequences, and understanding it helps make sense of why the weight loss outcomes differ so substantially.
The Mechanism Difference
Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone that reduces appetite, slows gastric emptying, and stimulates insulin secretion in a glucose-dependent manner. Brand names: Ozempic (diabetes, 2 mg/week max), Wegovy (weight management, 2.4 mg/week max).
Tirzepatide is a dual GIP/GLP-1 receptor agonist. In addition to everything semaglutide does at GLP-1 receptors, it also activates GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP acts on adipose tissue, muscle, and the brain in ways that appear to amplify the weight loss effects of GLP-1 receptor activation. Brand names: Mounjaro (diabetes), Zepbound (weight management).
The GIP mechanism is why tirzepatide produces greater weight loss. GIP appears to increase sensitivity to GLP-1 signaling and has additional effects on fat metabolism that GLP-1 alone doesn't replicate.
Clinical Trial Weight Loss Comparison
No head-to-head randomized controlled trial between tirzepatide and semaglutide has been published as of April 2026. Cross-trial comparisons have limitations (different populations, different dietary counseling, different trial lengths), but the data is instructive:
| Drug | Dose | Trial | Average Weight Loss |
|---|---|---|---|
| Tirzepatide | 15 mg/week | SURMOUNT-1 (72 weeks) | 22.5% |
| Tirzepatide | 10 mg/week | SURMOUNT-1 (72 weeks) | 19.5% |
| Tirzepatide | 5 mg/week | SURMOUNT-1 (72 weeks) | 15.0% |
| Semaglutide | 2.4 mg/week | STEP-1 (68 weeks) | 14.9% |
| Semaglutide | 1.0 mg/week | SUSTAIN-6 (104 weeks) | ~6% |
| Placebo | N/A | SURMOUNT-1 | 2.4% |
The SUPRASS-2 trial, which directly compared tirzepatide to semaglutide 1.0 mg for type 2 diabetes, showed tirzepatide at all doses outperformed semaglutide on both A1C reduction and weight loss. Tirzepatide 15 mg reduced A1C by 2.3% vs semaglutide's 1.86%, and produced about 12 lbs more weight loss on average.
A1C Reduction Comparison
For type 2 diabetes patients, A1C reduction is as important as weight loss.
| Drug | Max Approved Dose | Average A1C Reduction |
|---|---|---|
| Tirzepatide | 15 mg/week | 2.0–2.5% |
| Semaglutide (Ozempic) | 2 mg/week | 1.5–1.9% |
The tirzepatide advantage in A1C reduction is consistent across trials. For patients who need both better glycemic control and significant weight loss, tirzepatide has a clear clinical edge.
Side Effect Profile Comparison
Both drugs cause similar GI side effects: nausea, diarrhea, constipation, and vomiting. The profiles are nearly identical in character, though rates differ slightly:
- Nausea rates are comparable (30–33% on highest doses of each)
- Tirzepatide users report slightly more injection site reactions in some trials
- Semaglutide users report slightly more nausea in the initial weeks in some analyses
Neither drug is clearly better tolerated than the other at a population level. Individual patients often find one works better for them than the other. Anecdotally, some patients who switched from semaglutide to tirzepatide report fewer GI symptoms, though this is likely partly placebo and partly the different formulation.
Both drugs share the same class-level warnings: potential for pancreatitis, contraindicated with personal/family history of medullary thyroid carcinoma or MEN2.
Cost Comparison
| Drug | Brand | Retail Price | With Insurance/Savings |
|---|---|---|---|
| Tirzepatide | Mounjaro | ~$1,022/month | $25/month (Lilly savings card, insured) |
| Tirzepatide | Zepbound | ~$1,059/month | $25/month (Lilly savings card, insured) |
| Semaglutide | Ozempic | ~$935/month | Varies |
| Semaglutide | Wegovy | ~$1,349/month | ~$25/month (Novo Nordisk savings program) |
| Compounded tirzepatide | Various | $150–400/month | N/A |
| Compounded semaglutide | Various | $100–250/month | N/A |
Semaglutide compounded availability has also shifted post-shortage, similar to tirzepatide. Pricing is volatile.
For detailed tirzepatide cost breakdowns, see the complete tirzepatide cost guide.
Which Patients May Do Better on Each
Tirzepatide may be preferred when:
- Maximum weight loss is the primary goal
- The patient has significant insulin resistance or pre-diabetes
- Previous trial of semaglutide produced insufficient weight loss
- A1C reduction is a priority alongside weight loss
- Patient is comfortable with vial-based injection (for compounded) or pen injectors
Semaglutide may be preferred when:
- Insurance covers Ozempic/Wegovy but not Mounjaro/Zepbound
- Patient has history with semaglutide and good tolerance
- Cost is the primary constraint and compounded semaglutide is more available in their area
- Provider preference or formulary constraints
No clear winner for:
- GI side effect tolerance (similar between drugs)
- Cardiovascular benefit (both show CV benefit; SELECT trial for semaglutide, SURMOUNT-MMO ongoing for tirzepatide)
- Ease of use (both are weekly injections)
Switching From Semaglutide to Tirzepatide
Some patients switch from semaglutide to tirzepatide when weight loss plateaus or when they want to try the dual-agonist mechanism. This switch requires prescriber guidance on timing and starting dose.
Typically, you'd stop semaglutide and wait 1 week (roughly one half-life) before starting tirzepatide at the 2.5 mg initiation dose, then escalate normally. Don't jump to your semaglutide-equivalent dose. The different mechanism means tirzepatide escalation should be done from scratch.
Use the tirzepatide dosage calculator once you start compounded tirzepatide to confirm your injection volume. The dosing math is different from compounded semaglutide vials, which have their own concentration standards.
For a full breakdown of tirzepatide weight loss data, see what the research shows on tirzepatide results. For the standard dose ramp-up once you start, see the tirzepatide dosage schedule guide.
The about page has information on the clinical methodology behind this site's content.
Ready to calculate your dose?
Free tirzepatide injection volume calculator. No signup required.